This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Azoulay-Dupuis, E.
Right arrow Articles by Fantin, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Azoulay-Dupuis, E.
Right arrow Articles by Fantin, B.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Antibiotics
Hazardous Substances DB
*ERYTHROMYCIN

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2006, p. 3033-3038, Vol. 50, No. 9
0066-4804/06/$08.00+0     doi:10.1128/AAC.00920-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Efficacy of Cethromycin, a New Ketolide, against Streptococcus pneumoniae Susceptible or Resistant to Erythromycin in a Murine Pneumonia Model

E. Azoulay-Dupuis,* J. Mohler, J. P. Bédos, C. Barau, and B. Fantin

EA 3964, Faculté de Médecine de l'Université Paris VII, Paris, France

Received 20 July 2005/ Returned for modification 12 October 2005/ Accepted 28 May 2006

Cethromycin is a ketolide with in vitro activity against macrolide-sensitive and -resistant strains of Streptococcus pneumoniae. We compared its in vivo efficacy to erythromycin in a mouse model of acute pneumonia induced by two virulent clinical strains: a serotype 3 susceptible strain (P-4241) (MICs: erythromycin, 0.03 µg/ml; cethromycin, 0.015 µg/ml) and a serotype 1 strain resistant to erythromycin (P-6254; phenotypically MLSB constitutive) (MICs: erythromycin, 1,024 µg/ml; cethromycin, 0.03 µg/ml). Immunocompetent mice were infected with 105 CFU of each strain. Six treatments given either subcutaneously (s.c.) or per os (p.o.) at 12-h intervals were initiated at 6 or 12 h after infection. Against P-4241, cethromycin given s.c. at 25 or 12.5 mg/kg protected 100% of the animals, with lungs and blood completely cleared of bacteria. Given p.o., cethromycin maintained its efficacy with 100 and 86% survival at 25 and 12.5 mg/kg, respectively. Erythromycin, given s.c. at 50 or 37.5 mg/kg, provided 50 and 38% survival rates, respectively. Against P-6254, cethromycin was effective at 25 mg/kg (100% survival) regardless of the administration route, whereas only 25 and 8% of animals survived after a 75-mg/kg erythromycin treatment given s.c. and p.o., respectively. The serum protein binding levels of cethromycin were 94.8 and 88.5% after doses of 12.5 and 25 mg/kg, respectively. The higher in vivo activity of cethromycin compared to erythromycin could be explained by favorable pharmacokinetic/pharmacodynamic indexes against P-6254 but not against P-4241.

* Corresponding author. Mailing address: EA 3964, Faculté Xavier Bichat, 16, Rue Henri Huchard, 75870 Paris Cedex 18, France. Phone: (33) 1 44 85 61 53. Fax: (33) 1 44 85 61 47. E-mail: eazoulay{at}bichat.inserm.fr.

Antimicrobial Agents and Chemotherapy, September 2006, p. 3033-3038, Vol. 50, No. 9
0066-4804/06/$08.00+0     doi:10.1128/AAC.00920-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»